Salarius Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Salarius Pharmaceuticals, Inc. - overview
Established
2011
Location
Houston, TX, US
Primary Industry
Pharmaceuticals
About
Founded in 2011 and based in Texas, US, Salarius Pharmaceuticals, Inc. is a biotechnology company that develops therapeutics for the treatment of pediatric and other cancers, including advanced solid tumors, using epigenetic enzymes. The company develops Seclidemstat, a reversible LSD1 inhibitor for the treatment of Ewing sarcoma.
Current Investors
VisionTech Partners, Alexandria Venture Investments, Bessemer Venture Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.salariuspharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Salarius Pharmaceuticals, Inc. - timeline of key events
Salarius Pharmaceuticals, Inc. - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 1,010,663 | 1,274,499 | 838,142 | 3,465,055 | 5,233,301 | 1,840,216 | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 26.1% | (34.2%) | 313.4% | 51.0% | (64.8%) | - | - | - | - |
| EBITDA (USD) | (8,017,809) | (29,154,254) | (39,592,840) | (34,469,217) | (21,834,528) | (8,137,669) | (7,768,287) | (12,793,748) | (31,834,463) | - | - | - |
| Operating Income (USD) | (8,029,806) | (29,213,658) | (39,886,232) | (34,725,626) | (22,074,223) | (8,265,077) | (7,786,345) | (12,812,931) | (31,841,140) | - | - | - |
| Operating Margin | - | - | (3946.5%) | (2724.6%) | (2633.7%) | (238.5%) | (148.8%) | (696.3%) | - | - | - | - |
| % EBITDA Margin | - | - | (3917.5%) | (2704.5%) | (2605.1%) | (234.8%) | (148.4%) | (695.2%) | - | - | - | - |
| NET Income (USD) | (8,010,860) | (29,141,630) | (39,493,123) | (34,433,662) | (21,922,217) | (6,936,263) | (7,352,254) | (12,768,238) | (31,607,956) | - | - | - |
| % Net Margin | - | - | (3907.6%) | (2701.7%) | (2615.6%) | (200.2%) | (140.5%) | (693.8%) | - | - | - | - |
Salarius Pharmaceuticals, Inc. - employee data
Salarius Pharmaceuticals, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.